Clinical Trials Logo
  1. Home
  2. Psoriatic Arthritis
  3. NCT04800289
  4. Details
NCT04800289 Clinical Trial

Evaluation of Patient Satisfaction and Therapeutic Impact Regarding Joint Consultation Rheumatologist/Dermatologist

Psoriatic Arthritis Clinical Trial

— RHUMPSO  

Official title:
Evaluation of Patient Satisfaction and Therapeutic Impact Regarding Joint Consultation Rheumatologist/Dermatologist

Clinical Trial Details — Status: Recruiting

Administrative data
NCT number NCT04800289
Other study ID # CHM-2019/S7/11
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date July 19, 2020
Est. completion date July 31, 2030

Study information
Verified date March 2021
Source Centre Hospitalier le Mans
Contact Christelle JADEAU
Phone 02 43 43 43 43
Email cjadeau@ch-lemans.fr
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

Current increase in the number of multidisciplinary consultations, but little documentation on their impact on patient management. More specifically, in the context of psoriatic arthritis, we are seeking to investigate the interest for the patient, through his or her satisfaction and the evolution of the activity of his or her pathology, of a global, joint management in Rheumatology and Dermatology.

Recruitment information / eligibility
Status Recruiting
Enrollment 600
Est. completion date July 31, 2030
Est. primary completion date July 31, 2030
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - All patients received in a joint rheumatologist/dermatologist consultation at the Le Mans Hospital Exclusion Criteria: - Diagnosis of psoriatic arthritis not retained

Study Design

Related Conditions & MeSH terms

Intervention

Other:
• questionnaires
questionnaires about disease and satisfaction of patient

Locations
Country Name City State
France Centre Hospitalier Du Mans Le Mans

Sponsors (1)
Lead Sponsor Collaborator
Centre Hospitalier le Mans

Country where clinical trial is conducted

France, 

Outcome
Type Measure Description Time frame Safety issue
Primary impact on patient satisfaction and the evolution of their pathology of these mixed consultations, Dermatologist and Rheumatologist, in the context of psoriatic arthritis. evaluate the impact on patient satisfaction and the evolution of their pathology of these mixed consultations, Dermatologist and Rheumatologist, in the context of psoriatic arthritis. 5 years after inclusion
See also
  Status Clinical Trial Phase
Completed NCT04152759 - Comparative Study to Evaluate the Pharmacokinetics of BAT2506 vs Simponi® in Healthy Subjects Phase 1
Completed NCT03248518 - Lessening the Impact of Fatigue in Inflammatory Rheumatic Diseases N/A
Completed NCT01925768 - Safety and Efficacy Study of Apremilast to Treat Psoriatic Arthritis Phase 3
Completed NCT01892436 - Extension Study up to 3 Years for Secukinumab in Psoriatic Arthritis Phase 3
Completed NCT01212770 - PALACE 3: Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis Phase 3
Completed NCT05051943 - A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response
Completed NCT01212757 - PALACE 2: Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis Phase 3
Completed NCT03953378 - CD73+ Th1.17 in Rheumatoid Arthritis and Psoriatic Arthritis
Recruiting NCT02572700 - Pain Mechanisms and Ultrasonographic Disease Activity in Psoriatic Arthritis
Completed NCT02556034 - Assessment of Tender & Swollen Joints Count Score Performed by a Rheumatologist And Rheumatology Nurses in Patients With RA and PsA.
Completed NCT02154425 - A Multicenter, Postmarketing Study Evaluating the Concentration of Cimzia® in Mature Breast Milk of Lactating Mothers Phase 1
Completed NCT02188654 - Metformin in Psoriatic Arthritis N/A
Completed NCT01392326 - Efficacy at 24 Weeks and Long Term Safety, Tolerability and Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Psoriatic Arthritis (PsA) Phase 3
Completed NCT02164214 - Does Etanercept Influence Tweak Modulation of Inflammation During Inflammatory Rheumatisms (Psoriatic Arthritis and Rheumatoid Arthritis)? Phase 3
Completed NCT01083693 - Quality of Life Outcomes of HUMIRA in Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA), Ankylosing Spondylitis (AS) After Unsustainable Response to Biologicals and Disease Modifying Antirheumatic Drugs N/A
Not yet recruiting NCT00517101 - Presence of IBD Specific Antibodies (ASCA, ALCA, ACCA, AMCA) in the Sera of Patients With Spondyloarthropathy N/A
Completed NCT00133315 - TNFalfa Blocking Treatment of Spondylarthropathies Phase 4
Completed NCT00659412 - A Placebo-controlled Study With an Extension Examining the Safety and Efficacy of Alefacept in Psoriatic Arthritis Phase 2
Completed NCT00946686 - To Demonstrate the Relative Bioavailability, Parallel Study Of Leflunomide 20 mg Tablets Under Fasting Conditions Phase 1
Not yet recruiting NCT06059430 - Cohort Project of Patients With Inflammatory Rheumatism